HRP20070175T3 - (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist - Google Patents
(s)-2-n-propylamino-5-hydroxytetralin as a d3-agonistInfo
- Publication number
- HRP20070175T3 HRP20070175T3 HR20070175T HRP20070175T HRP20070175T3 HR P20070175 T3 HRP20070175 T3 HR P20070175T3 HR 20070175 T HR20070175 T HR 20070175T HR P20070175 T HRP20070175 T HR P20070175T HR P20070175 T3 HRP20070175 T3 HR P20070175T3
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxytetralin
- propylamino
- agonist
- nhr2
- nr2r3
- Prior art date
Links
- VCYPZWCFSAHTQT-NSHDSACASA-N (6s)-6-(propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C[C@@H](NCCC)CCC2=C1O VCYPZWCFSAHTQT-NSHDSACASA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- -1 cycloalkoxycarbonyl Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10359528A DE10359528A1 (de) | 2003-12-18 | 2003-12-18 | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| PCT/EP2004/014143 WO2005058296A1 (de) | 2003-12-18 | 2004-12-13 | (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20070175T3 true HRP20070175T3 (en) | 2007-06-30 |
Family
ID=34683532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20070175T HRP20070175T3 (en) | 2003-12-18 | 2007-04-23 | (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8609641B2 (pt) |
| EP (1) | EP1694318B1 (pt) |
| JP (1) | JP5253737B2 (pt) |
| KR (1) | KR101083568B1 (pt) |
| CN (1) | CN1929829B (pt) |
| AT (1) | ATE356621T1 (pt) |
| AU (1) | AU2004298341B2 (pt) |
| BR (1) | BRPI0417739A (pt) |
| CA (1) | CA2547820C (pt) |
| CY (1) | CY1106589T1 (pt) |
| DE (2) | DE10359528A1 (pt) |
| DK (1) | DK1694318T3 (pt) |
| ES (1) | ES2282923T3 (pt) |
| HK (1) | HK1094421A1 (pt) |
| HR (1) | HRP20070175T3 (pt) |
| IS (1) | IS2533B (pt) |
| MX (1) | MXPA06006696A (pt) |
| PL (1) | PL1694318T3 (pt) |
| PT (1) | PT1694318E (pt) |
| RS (1) | RS50536B (pt) |
| SI (1) | SI1694318T1 (pt) |
| WO (1) | WO2005058296A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| SG10201610626PA (en) * | 2007-11-28 | 2017-01-27 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
| WO2010043571A1 (en) * | 2008-10-13 | 2010-04-22 | Interquim, S.A. | Process for the preparation of optically active (s)-(-)-2-(n-propylamino)-5-methoxytetraline and (s)-(-)-2-(n-propylamino)-5-hydroxytetraline compounds |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| JP5738875B2 (ja) * | 2009-10-16 | 2015-06-24 | エピオメド セラピューティクス， インク． | 催吐治療 |
| EP3257504A1 (en) | 2009-12-22 | 2017-12-20 | UCB Biopharma SPRL | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| CN103282369A (zh) * | 2011-04-08 | 2013-09-04 | 劳乐斯实验室私营有限公司 | 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物 |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| CN102634064B (zh) * | 2012-04-10 | 2013-09-11 | 宁波长阳科技有限公司 | 一种含磷阻燃剂、阻燃聚酯薄膜及其制备方法 |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2021206741A1 (en) * | 2020-04-09 | 2021-10-14 | Delahoussaye Kevin | Modulating neurotransmitter concentration |
| DE102021213721A1 (de) * | 2021-12-02 | 2023-06-07 | Continental Reifen Deutschland Gmbh | Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Farbstoff |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1017359A (en) * | 1972-07-03 | 1977-09-13 | Frederic P. Hauck | Substituted cyclic polymethylene phenols |
| DE3062971D1 (en) * | 1979-09-14 | 1983-06-09 | Sandoz Ag | Derivatives of tetraline, their preparation and medicaments containing these compounds |
| US4465692A (en) * | 1982-01-03 | 1984-08-14 | Nelson Research & Development Company | Selective D-2 dopamine receptor agonist |
| US5177112A (en) * | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| FR2563731B1 (fr) * | 1984-05-07 | 1989-03-24 | Nelson Res & Dev | Composition therapeutique contenant de la 2-(n-phenylethyl-n-propylamino)-5-hydroxytetraline pour traiter la maladie de parkinson, pour stimuler selectivement les recepteurs de dopamine d-2 et procede de production d'une composition pharmaceutique utile au traitement de la maladie de parkinson |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| AU4312593A (en) | 1992-05-18 | 1993-12-13 | Smithkline Beecham Plc | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease |
| SE9301732D0 (sv) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins |
| US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US5442117A (en) * | 1993-12-13 | 1995-08-15 | Albemarle Corporation | Enantiomeric resolution |
| IT1292155B1 (it) | 1997-06-13 | 1999-01-25 | Zambon Spa | Derivati naftotiazolonici attivi sul recettore dopaminergico d 3 |
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| CN1185225C (zh) * | 1999-11-23 | 2005-01-19 | 阿德里斯制药公司 | 制备氮取代的氨基1,2,3,4－四氢化萘的改进方法 |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| PT1256340E (pt) | 2001-05-08 | 2003-12-31 | Sanol Arznei Schwarz Gmbh | Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson |
| DE60100994T2 (de) | 2001-05-08 | 2004-07-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| FR2829028B1 (fr) * | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| HU227543B1 (en) | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| HUP0103986A2 (hu) * | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| US20040034083A1 (en) * | 2002-04-18 | 2004-02-19 | Stephenson Diane T. | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| EP1426049B1 (en) * | 2002-12-02 | 2005-05-18 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| SG10201610626PA (en) * | 2007-11-28 | 2017-01-27 | Ucb Pharma Gmbh | Polymorphic form of rotigotine |
| EP2281559A1 (en) * | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| EP3257504A1 (en) * | 2009-12-22 | 2017-12-20 | UCB Biopharma SPRL | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
-
2003
- 2003-12-18 DE DE10359528A patent/DE10359528A1/de not_active Ceased
-
2004
- 2004-12-13 PL PL04803781T patent/PL1694318T3/pl unknown
- 2004-12-13 PT PT04803781T patent/PT1694318E/pt unknown
- 2004-12-13 MX MXPA06006696A patent/MXPA06006696A/es active IP Right Grant
- 2004-12-13 DE DE502004003249T patent/DE502004003249D1/de active Active
- 2004-12-13 CA CA2547820A patent/CA2547820C/en not_active Expired - Fee Related
- 2004-12-13 SI SI200430278T patent/SI1694318T1/sl unknown
- 2004-12-13 EP EP04803781A patent/EP1694318B1/de active Active
- 2004-12-13 AU AU2004298341A patent/AU2004298341B2/en not_active Ceased
- 2004-12-13 AT AT04803781T patent/ATE356621T1/de active
- 2004-12-13 US US10/587,637 patent/US8609641B2/en not_active Expired - Fee Related
- 2004-12-13 JP JP2006544295A patent/JP5253737B2/ja not_active Expired - Fee Related
- 2004-12-13 DK DK04803781T patent/DK1694318T3/da active
- 2004-12-13 CN CN2004800373891A patent/CN1929829B/zh not_active Expired - Fee Related
- 2004-12-13 RS RSP-2007/0117A patent/RS50536B/sr unknown
- 2004-12-13 WO PCT/EP2004/014143 patent/WO2005058296A1/de active Application Filing
- 2004-12-13 ES ES04803781T patent/ES2282923T3/es active Active
- 2004-12-13 BR BRPI0417739-8A patent/BRPI0417739A/pt not_active Application Discontinuation
-
2006
- 2006-06-12 KR KR1020067011512A patent/KR101083568B1/ko not_active IP Right Cessation
- 2006-06-12 IS IS8505A patent/IS2533B/is unknown
-
2007
- 2007-02-05 HK HK07101358A patent/HK1094421A1/xx not_active IP Right Cessation
- 2007-04-23 HR HR20070175T patent/HRP20070175T3/xx unknown
- 2007-05-14 CY CY20071100652T patent/CY1106589T1/el unknown
-
2013
- 2013-10-25 US US14/063,821 patent/US9108900B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0417739A (pt) | 2007-04-03 |
| MXPA06006696A (es) | 2006-08-31 |
| CN1929829B (zh) | 2010-12-15 |
| PL1694318T3 (pl) | 2007-07-31 |
| CA2547820C (en) | 2013-02-19 |
| JP2007514674A (ja) | 2007-06-07 |
| CA2547820A1 (en) | 2005-06-30 |
| IS8505A (is) | 2006-06-12 |
| US20070197480A1 (en) | 2007-08-23 |
| DE10359528A1 (de) | 2005-07-28 |
| IS2533B (is) | 2009-07-15 |
| AU2004298341B2 (en) | 2011-03-10 |
| KR101083568B1 (ko) | 2011-11-14 |
| PT1694318E (pt) | 2007-05-31 |
| SI1694318T1 (sl) | 2007-08-31 |
| CY1106589T1 (el) | 2012-01-25 |
| WO2005058296A1 (de) | 2005-06-30 |
| ES2282923T3 (es) | 2007-10-16 |
| US9108900B2 (en) | 2015-08-18 |
| CN1929829A (zh) | 2007-03-14 |
| DE502004003249D1 (en) | 2007-04-26 |
| ATE356621T1 (de) | 2007-04-15 |
| KR20060126500A (ko) | 2006-12-07 |
| US8609641B2 (en) | 2013-12-17 |
| JP5253737B2 (ja) | 2013-07-31 |
| AU2004298341A1 (en) | 2005-06-30 |
| US20140051768A1 (en) | 2014-02-20 |
| EP1694318B1 (de) | 2007-03-14 |
| EP1694318A1 (de) | 2006-08-30 |
| RS50536B (sr) | 2010-05-07 |
| HK1094421A1 (en) | 2007-03-30 |
| DK1694318T3 (da) | 2007-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20070175T3 (en) | (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist | |
| HRP20030091B1 (en) | 9-substituted minocycline compounds | |
| RS53279B (en) | MONODISPERSE MIXTURES OF PEGYLATED NALOXOL | |
| RS51973B (en) | STABLE PHARMACEUTICAL PRODUCTS CONTAINING FEZOTERODINE | |
| ECSP066493A (es) | Combinaciones sinérgicas de productos activos, fungicidas | |
| WO2004014902A8 (en) | Compounds having an activity at metabotropic glutamate receptors | |
| AR027437A1 (es) | Derivados de purina | |
| RS50534B (sr) | Intranazalna formulacija rotigotina | |
| RS51394B (en) | SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS | |
| NO20032233L (no) | Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| RS52865B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
| UY26512A1 (es) | Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| GT200000183A (es) | Aminoacidos biciclicos como agentes farmaceuticos. | |
| DE59706313D1 (de) | Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung | |
| WO2009064374A3 (en) | Oral formulations of bis(thiohydrazide amides) | |
| AU2002343174A1 (en) | Betaine and salicylic acid compositions | |
| EA200500240A1 (ru) | Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| AU5471796A (en) | RARgamma-specific retinobenzoic acid derivatives | |
| BRPI0409105A (pt) | análogos de quinobenzoxazina substituìdos | |
| MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
| AR029343A1 (es) | USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN | |
| WO2003035610A1 (fr) | Derive de sulfonamide a effet inhibiteur sur les mmp |